Research on drug repositioning opens a new path toward innovative therapeutic options in the treatment of cancer.»
A class of drugs used for heart failure treatment have been known to protect patients with heart failure from cancer by reducing cancer rate and mortality. At CHU Sainte-Justine in Montreal, Noël Raynal and his team have managed to understand how these drugs target cancer cells and for which cancers they should be repurposed. To bring this exciting repurposing program to clinical trials, the team will demonstrate the efficacy of these drugs in vivo.
"Each cancer is unique, and to increase the chances of survival, precision medicine is a promising way forward by developing patient-specific therapeutic strategies. It is therefore essential to analyze the different characteristics of each cancer in genomics, epigenetic and proteomic terms in order to identify optimal therapies. Research on drug repositioning opens a new path toward innovative therapeutic options in the treatment of cancer. "
The Cancer Research Society funds highly promising research projects undertaken by Canada’s best scientists. Following a rigorous peer review selection process, about 150 researchers are thus able to advance scientific knowledge to improve cancer prevention, detection and treatments, through various funding programs. These programs are based on scientific excellence, support to new generations of scientists, support to promising underfunded research avenues and partnerships with great impact potential. Since its inception, the Cancer Research Society has thus contributed to major advances in oncology, helping position Canada at the forefront of cancer research in the world.